SHR-A1912

N/A

Report date: 2025/05/30 15:59:53

Base Information

Drug NameSHR-A1912
Drug Alias NameSHR-A1912
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD79BDNA topoisomerase I inhibitors
TargetsB-cell antigen receptor complex-associated protein beta chainDNA topoisomerase I
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A